Trailing Twelve Months Revenue Growth: I-Mab (IMAB)

Public company logo of I-Mab Biopharma Co., Ltd. (IMAB)

I-Mab is undergoing a large-scale resource reallocation following a structural split, which maintains high risk volatility. The business model is based on selling antibody rights to Western corporations after primary testing in China, thereby minimizing capital expenditures. Success depends on the effectiveness of the immunotherapy portfolio and the regulatory environment. This chart of the rolling 12-month YoY revenue growth demonstrates real sales dynamics, where the indicator reached the level of 0.00.

I-Mab Biopharma (IMAB): Revenue Growth YoY (Last 12 Months) from 02/11/2024 to 02/20/2024

I-Mab Biopharma - analytical breakdowns and key metrics (IMAB)

- stock price and consensus target price:
- company stock exchange capitalization indicators:
Summary company analytics:i-mabbiopharma.com
Brand item of i-mabbiopharma.com

To minimize risks, investors should track demand dynamics for I-Mab (IMAB) drugs, utilizing relative revenue growth over the last four quarters compared to the previous year as a filter for market cycles. Portfolio diversification of antibodies and global partnerships ensure stability, while an upward trend in this indicator confirms the actual expansion of the company's commercial presence, preventing overpayment for fading business development momentum.

Who I-Mab competes with

Incyte Pharma - Sales Growth YoY (Last Twelve Months)|HUTCHMED Corp - Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth Nuvation Bio Inc.|DAWN: Sales Growth YoY (TTM)|Revenue Growth Rate YoY (Last Twelve Months) Monopar Pharma MNPR|Revenue Growth YoY (Last 12 Months) INBX|Trailing Twelve Months Revenue Growth Fennec Pharmaceuticals FENC|Revenue Growth YoY (Last 12 Months) HRTX (Heron)|NVCT (Nuvectis Pharma) - Revenue Dynamics YoY (Last Twelve Months)|Coherus Biosciences - Revenue Growth YoY (Last 12 Months)|Revenue Change YoY (Last 12 Months) CRBP (Corbus Pharmaceuticals Holdings)|Cardiff Oncology - Sales Growth YoY (TTM)|Revenue Dynamics YoY (Last Twelve Months) BYSI (BeyondSpring Pharma)|BCAB: Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth lixte.com (LIXT)|Sales Growth YoY (Last Twelve Months) citiuspharma.com|CLRB: Revenue Dynamics YoY (Last Twelve Months)|Sales Growth YoY (TTM) BLRX|Sales Growth YoY (TTM) Can-Fite (CANF)|Sales Growth YoY (Last Twelve Months) Aprea Therapeutics Inc. APRE|KZIA (kaziatherapeutics.com) - Trailing Twelve Months Sales Growth|SLXN: Revenue Growth YoY (Last 12 Months)|Trailing Twelve Months Revenue Growth NuCana|CMRX: Sales Growth YoY (TTM)|Revenue Growth YoY (Last 12 Months) Cyclacel Pharmaceuticals|GTHX (g1therapeutics.com) - Sales Growth YoY (TTM)|KRON: Revenue Dynamics YoY (Last Twelve Months)|Sales Growth YoY (Last Twelve Months) Kintara (KTRA)|Revenue Growth YoY (Last 12 Months) Oncternal ONCT|Portage Biotech - Revenue Growth YoY (Last 12 Months)